株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

網膜静脈閉塞 (RVO) の予測:主要8市場

Epiomic Epidemiology Series: Retinal Vein Occlusion Forecast in 8 Major Markets 2015-2025

発行 Black Swan Analysis 商品コード 339835
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
網膜静脈閉塞 (RVO) の予測:主要8市場 Epiomic Epidemiology Series: Retinal Vein Occlusion Forecast in 8 Major Markets 2015-2025
出版日: 2015年08月11日 ページ情報: 英文 40 Pages
概要

世界において網膜静脈閉塞 (RVO) は網膜の一般的な血管障害であり、失明の最大の原因のひとつです。

当レポートでは、主要8市場 (米国、フランス、ドイツ、イタリア、スペイン、英国、ブラジル、日本) における網膜静脈閉塞 (RVO) の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

図表

概要

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/症候

患者数の定量化方法

網膜静脈閉塞 (RVO) の有病率トップライン

網膜静脈閉塞 (RVO) の主なタイプ

網膜静脈閉塞 (RVO) の発生部位

網膜中心静脈閉塞症 (CRVO)

  • CRVOの合併症

網膜静脈分枝閉塞症 (BRVO)

  • BRVOの合併症

参考文献

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RETV0010815

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Retinal Vein Occlusion in 8 Major Markets

Retinal Vein Occlusion (RVO) is a common vascular disorder of the retina and one of the most common causes of vision loss worldwide. It is caused by the blockage of a portion of the venous circulation that drains the retina and can result in haemorrhage and fluid loss. This report provides the current prevalent population for RVO across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of RVO. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of RVO have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for RVO include:

  • Visual complications
  • Blindness
  • Cardiovascular diseases
  • Diabetes mellitus
  • Hypertension
  • Glaucoma
  • Dense Muscular haemorrhage

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy:

  • Able to quantify patient populations in global RVO's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of RVO and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on RVO's prevalent population.
  • Identify sub-populations within RVO which require treatment.
  • Gain an understanding of the specific markets that have the largest number of RVO patients.

Table of Contents

  • List of Tables & Figures
  • Overview
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis &Clinical Course
  • Key Comorbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line RVO Prevalence
  • Main Type of RVO
  • Occlusion location of RVO
  • Central RVO
    • Co-morbidities within CRVO
  • Branch RVO
    • Co-morbidities within BRVO
  • References
  • Appendix

List of Tables & Figures

  • Prevalence of RVO, total (000s)
  • Prevalence of RVO, males (000s)
  • Prevalence of RVO, females (000s)
  • RVO by vein affected, total (000s)
  • Main occlusion location for RVO, total (000s)
  • Prevalence of CRVO by main aetiology, total (000s)
  • Glaucoma by type within CRVO, total (000s)
  • Prevalence of Diabetes in CRVO, total (000s)
  • Prevalence of Hypertension in CRVO, total (000s)
  • Prevalence of BRVO by main type, total (000s)
  • Macular status at diagnosis of BRVO, total (000s)
  • Glaucoma by type within BRVO, total (000s)
  • Prevalence of Diabetes in BRVO, total (000s)
  • Prevalence of Hypertension in BRVO, total (000s)
  • Prevalence of Dense macular haemorrhage in BRVO, total (000s)
  • USA Prevalence of RVO by 5-yr age cohort, males (000s)
  • USA Prevalence of RVO by 5-yr age cohort, females (000s)
  • France Prevalence of RVO by 5-yr age cohort, males (000s)
  • France Prevalence of RVO by 5-yr age cohort, females (000s)
  • Germany Prevalence of RVO by 5-yr age cohort, males (000s)
  • Germany Prevalence of RVO by 5-yr age cohort, females (000s)
  • Italy Prevalence of RVO by 5-yr age cohort, males (000s)
  • Italy Prevalence of RVO by 5-yr age cohort, females (000s)
  • Spain Prevalence of RVO by 5-yr age cohort, males (000s)
  • Spain Prevalence of RVO by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of RVO by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of RVO by 5-yr age cohort, females (000s)
  • Brazil Prevalence of RVO by 5-yr age cohort, males (000s)
  • Brazil Prevalence of RVO by 5-yr age cohort, females (000s)
  • Japan Prevalence of RVO by 5-yr age cohort, males (000s)
  • Japan Prevalence of RVO by 5-yr age cohort, females (000s)
Back to Top